In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation

dc.contributor.authorRomo, Jesus A.
dc.contributor.authorPierce, Christopher G.
dc.contributor.authorEsqueda, Marisol
dc.contributor.authorHung, Chiung-Yu
dc.contributor.authorSaville, Stephen P.
dc.contributor.authorLopez-Ribot, Jose L.
dc.date.accessioned2023-06-14T18:30:10Z
dc.date.available2023-06-14T18:30:10Z
dc.date.issued2018-07-10
dc.description.abstractWe have previously identified a small molecule compound, N-[3-(allyloxy)-phenyl]-4-methoxybenzamide (9029936), that exerts potent inhibitory activity against filamentation and biofilm formation by the Candida albicans SC5314 strain and represents a lead candidate for the development of anti-virulence approaches against C. albicans infections. Here we present data from a series of experiments to further characterize its in vitro activity and drug-like characteristics. We demonstrate the activity of this compound against a panel of C. albicans clinical isolates, including several displaying resistance to current antifungals; as well as against a set of C. albicans gain of function strains in key transcriptional regulators of antifungal drug resistance. The compound also inhibits filamentation and biofilm formation in the closely related species C. dubliniensis, but not C. glabrata or C. tropicalis. Combinatorial studies reveal the potential of compound 9029936 to be used together with currently available conventional antifungals. Results of serial passage experiments indicate that repeated exposure to this compound does not elicit resistance. Viability staining of C. albicans in the presence of high concentrations of compound 9029936 confirms that the compound is not toxic to fungal cells, and cytological staining using image flow cytometry analysis reveals that treatment with the lead compound affects hyphal length, with additional effects on cell wall and integrity of the membrane system. In vitro pharmacological profiling provides further evidence that the lead compound displays a safe profile, underscoring its excellent “drug-like” characteristics. Altogether these results confirm the potential of this compound to be further developed as a true anti-virulence agent for the treatment of C. albicans infections, including those refractory to treatment with conventional antifungal agents.en_US
dc.description.departmentMolecular Microbiology and Immunologyen_US
dc.description.sponsorshipNational Institute of Allergy and Infectious Diseases; Margaret Batts Tobin Foundation, San Antonio, TX; UTSA RISE-Ph.D. Trainee Programen_US
dc.identifier.citationRomo, J. A., Pierce, C. G., Esqueda, M., Hung, C.-Y., Saville, S. P., & Lopez-Ribot, J. L. (2018). In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation. Frontiers in Cellular and Infection Microbiology, 8. doi:10.3389/fcimb.2018.00227en_US
dc.identifier.issn2235-2988
dc.identifier.otherhttps://doi.org/10.3389/fcimb.2018.00227
dc.identifier.urihttps://hdl.handle.net/20.500.12588/1879
dc.language.isoen_USen_US
dc.publisherFrontiers Mediaen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectCandida albicansen_US
dc.subjectcandidiasisen_US
dc.subjectbiofilmsen_US
dc.subjectfilamentationen_US
dc.subjectanti-virulence drugsen_US
dc.titleIn Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formationen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Romo 2018 - In Vitro Characterization of a Biaryl Amide Anti-virulence Compound Targeting Candida albicans Filamentation and Biofilm Formation.pdf
Size:
6.57 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.86 KB
Format:
Item-specific license agreed upon to submission
Description: